Specimen Repository for HIV Immunopathogenesis

HIV-1-infection Clinical Trial

Official title:

Specimen Repository for HIV Immunopathogenesis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03579381
• Other study ID #: AHF 03
• Status: Completed
• Start date: July 31, 2017
• Est. completion date: January 25, 2019

Study information

• Verified date: January 2021
• Source: AIDS Healthcare Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Specimen Repository for HIV Immunopathogenesis Studies

Description:

The goal is to build a large specimen repository for collaborating scientists to run studies of immunity and HIV-1.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: January 25, 2019
• Est. primary completion date: January 25, 2019
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. HIV positive (acutely infected, viremic and elite controllers)

2. Signed Informed Consent Form

3. Age at least 18 years old

4. Immune controllers, two types: "Elite suppressors" (HIV-positive with any three consecutive plasma HIV-1 RNA PCR undetectable while off treatment) or "viremic suppressors" (HIV-positive with any three consecutive HIV-1 RNA PCR <3000 while off treatment).

5. Acutely infected subjects:

Persons identified to have a negative HIV antibody response (ELISA) but positive detection of HIV-1 in the blood (RT-PCR) or individuals who have evidence of a recent (past 30 days) HIV negative result along with a current HIV positive result.

Exclusion Criteria:

1. Uncontrolled bleeding diathesis.

2. Pregnant.

3. Inability to provide informed consent.

Related Conditions & MeSH terms

• Acute HIV Infection
• Communicable Diseases
• HIV-1-infection
• Infection

Locations

Country	Name	City	State
United States	AIDS Healthcare Foundation - Public Health Division	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
AIDS Healthcare Foundation	University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HIV progression from acute infection to viral suppression	Outcomes will depend on scientists who use the samples for further study	2 years
Primary	HIV progression and control by elite and viremic suppressors	Outcomes will depend on scientists who use the samples for study	2 years